A new class of migraine drugs, called anti-CGRPs (calcitonin gene-related peptide) are expected to reinvigorate a market that has been largely dormant for some time. Four biopharma companies, Amgen, Teva, Lilly and Alder are entering the fray. Not surprisingly, the intense competition and pharma investment associated with this market dynamic has led traditional “eyeball driven” publishers, like WebMD, Everyday Health and others on a quest to offer substantially more migraine-related content in reaction to this market opportunity.